Thromb Haemost 1981; 46(01): 379
DOI: 10.1055/s-0038-1653139
Antithrombin III Heparin
Schattauer GmbH Stuttgart

Prevention Of Deep Vein Thrombosis In Medical Patients By Low Dose Subcutaneous Heparin

Authors

  • J J F Belch

    University Department of Medicine, Royal Infirmary, Glasgow, Scotland
  • G D O Lowe

    University Department of Medicine, Royal Infirmary, Glasgow, Scotland
  • A G Ward

    University Department of Medicine, Royal Infirmary, Glasgow, Scotland
  • C D Forbes

    University Department of Medicine, Royal Infirmary, Glasgow, Scotland
  • C R M Prentice

    University Department of Medicine, Royal Infirmary, Glasgow, Scotland
Further Information

Publication History

Publication Date:
26 July 2018 (online)

Preview

In recent years it has been repeatedly shown that low-dose subcutaneous heparin reduces the incidence of deep vein thrombosis (D.V.T.) after major general surgery. By comparison, the prevention of thrombosis in medical patients has been little studied. A randomised trial was undertaken in one hundred patients with heart failure and/or chest infection to determine whether low-dose subcutaneous heparin reduced the frequency of D.V.T. in the legs. Heparin (5000 units 8 hourly), started within 12 hours of admission to hospital and continued until the patient was fully mobile, significantly reduced the frequency of D.V.T. diagnosed by the 125I- fibrinogen scan technique, from 26% to 4% (p<0.01). Heparin did not cause bleeding problems except for a 20% incidence of injection site bruising. We therefore recommend prophylaxis with low dose subcutaneous heparin in patients with heart failure or chest infection who require more than 3 days’ bed rest.